logo
The Best Thing About the Proposed California Initiative Named After Luigi Mangione Is the Title

The Best Thing About the Proposed California Initiative Named After Luigi Mangione Is the Title

Yahoo31-03-2025

His name and likeness have appeared on t-shirts, in graffiti, and in so, so many memes. Now, Luigi Mangione, the alleged killer of UnitedHealthcare CEO Brian Thompson, might have his name end up in a California law as well.
Over the weekend, California news outlets reported that a proposed ballot initiative titled the "Luigi Mangioni [sic] Access to Healthcare Act" had been submitted to the California Attorney General's Office for review.
The proposed initiative's title is predictably drawing a lot of attention, as it is named after an alleged murderer.
The proposed initiative's author, retired Los Angeles-based attorney Paul Eisner, says that's kind of the whole point. "It is getting the attention it needs because sometimes things require publicity," Eisner told CBS 8.
While it has certainly attracted publicity, the controversy over the proposed ballot initiative's working title has distracted people from its even worse substance.
Eisner's proposal states that no insurer may "delay, deny, or modify any medical procedure or medication" recommended by a treating physician—or even demand reduced payment for such treatments—if doing so could result in disability, death, permanent disfigurement, or the loss or reduction of "any bodily function."
Insurers would have to rely on their own doctors to deny a claim or reduce payment for a procedure. If an insurer is sued for denying a claim, they would have to prove with "clear and convincing" evidence that the procedure is unnecessary. This would mean that an insurer couldn't argue they are denying a claim because the provider's proposed costs are outrageously high.
The consequences of this initiative would be sweeping and probably fatal for private insurance in California.
Almost every treatment a doctor would recommend could plausibly be defended as at least protecting some bodily function. Proving that a treatment is in fact unnecessary would be a very high bar indeed.
In effect, the ballot initiative would put insurers in a position of either immediately approving every claim submitted to them or fighting a lawsuit that they'd almost certainly lose.
Since the ballot initiative guarantees successful litigants against insurance companies treble damages and attorneys fees, anyone whose claim was denied would have a major incentive to sue.
Because the initiative effectively prohibits insurers from even reducing payment for a procedure, they would also effectively lose their ability to bargain with healthcare providers over prices.
That would give healthcare providers a very obvious incentive to raise prices on all their services.
At a minimum, insurers would have to massively raise premiums to cover the new costs they'd be exposed to under this proposed system. Spiking premiums would see them shed customers, and plausibly go out of business completely.
One couldn't imagine a better system for creating an insurer "death spiral."
It is easy to dismiss Eisner's proposed ballot initiative as an unserious effort. He's just one guy proposing a ballot initiative. He still needs approval from the attorney general to start collecting signatures in order to actually get it on the ballot. And he even spelled Mangione's name wrong in his application.
Nevertheless, California has a history of gadflies getting far-reaching policies on the ballot that then end up winning. Liberal California likes to point to Proposition 13, which limited property tax increases, as the canonical example of this.
Another example would be Proposition 103, a 1988 initiative pushed by consumer advocates that created California's current regulatory regime for property and auto insurance.
Prop. 103 limits insurers' ability to raise rates on policyholders and creates a laborious system to justify whatever price increases they are still permitted.
This has prevented insurers from incorporating increasing wildfire risks into their rates. As wildfire damages have mounted in recent years, insurers have responded to Prop 103's incentives by limiting the business they do in California wherever possible.
The design of Eisner's initiative is slightly different. It would effectively mandate higher insurance payouts as opposed to capping upfront insurance costs.
But like Prop. 103, his initiative treats insurance companies as a source of endless money that faces no resource constraints and whose policies need not be based on market prices.
As much as people dislike insurance companies, they play an important role in America's healthcare system. They're one of the few institutional actors that has an incentive to actually keep healthcare costs down.
That's not an argument that typically resonates with the public. The widespread view of insurance companies as malevolent actors is one of the reasons why Mangione's alleged crime has turned him into a dark folk hero.
Fortunately, most people still find murder bad, even if the victim is a despised insurance executive.
Even Eisner can't bring himself to fully endorse Mangione. In his comments to CBS 8, Eisner condemned Mangione's alleged violent tactics, saying instead that he was trying to do things "the right way."
While it certainly generated a lot of publicity, it's likely that Eisner's proposed ballot title will sap support for a ballot initiative that could conceivably have passed had it not been named after an alleged murderer.
In that way, the best thing about Eisner's proposed initiative is its repulsive title. It'll turn people off from voting for a potentially popular, truly destructive policy.
The post The Best Thing About the Proposed California Initiative Named After Luigi Mangione Is the Title appeared first on Reason.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Yahoo

time28 minutes ago

  • Yahoo

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals. 'We are excited by these impressive results from MET-233i, which demonstrate exceptional efficacy with no safety signals, and enable the potential first monthly multi-NuSH combination,' said Steve Marso, M.D., Chief Medical Officer of Metsera. 'We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i.' The randomized, placebo-controlled, double-blind Phase 1 trial was designed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous MET-233i in 80 participants with overweight or obesity without type 2 diabetes. MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial population was broadly balanced in gender between MET-233i and placebo and had a mean baseline body mass index of approximately 32. Topline results from the Phase 1 trial include: Dose-linear pharmacokinetics with an observed half-life of 19 days from dose to 50% of Cmax. This represents the most durable pharmacokinetic profile of any known amylin analog and supports the potential for once-monthly dosing with simplified titration. MET-233i's exposure profile after multiple doses matched that of MET-097i, supporting combinability as a potential first-in-category once-monthly multi-NuSH combination. These data further substantiate HALO™, Metsera's proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%. Body weight loss was dose-dependent, ranging up to a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. In the single ascending dose (SAD) portion of the trial, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i. Favorable tolerability results. Gastrointestinal adverse events in the multiple ascending dose (MAD) portion of the trial were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid onset of tolerance despite a three-fold accumulation of exposure over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the SAD and the MAD portions of the trial. No safety signals. There were no severe or serious adverse events observed in the SAD or MAD portion of the trial to date. 'Amylin agonism has emerged as a central therapeutic mechanism for metabolic diseases, but candidates in development have been limited to weekly dosing,' said Professor Carel le Roux, Director of the Metabolic Medicine Group and Chair in Experimental Pathology at University College Dublin. 'The durability and efficacy of MET-233i in this trial, along with its combinability with Metsera's GLP-1 RA, make it the potential first monthly multi-NuSH combination candidate for patients seeking greater levels of well-tolerated weight loss with a more convenient dosing schedule.'Next StepsBased on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025. Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026. The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera's HALO™ platform to enter clinical Call and Webcast InformationMetsera will host a conference call and webcast today, June 9, 2025, at 8:00 A.M. Eastern Time to discuss the Phase 1 clinical trial of MET-233i. A live webcast of the call and a replay will be available on the Events page in the Investors & News section of the Metsera website at To access the call by phone, participants should visit this link to receive dial-in details: About MET-233i MET-233i is an ultra-long acting, subcutaneously injectable monthly amylin analog engineered for class-leading durability, potency, and combinability in solution with Metsera's fully-biased, ultra-long acting GLP-1 RA candidate MET-097i, with matched solubility parameters and observed half-lives. MET-233i is being explored in clinical studies as a monotherapy and in combination with MET-097i. Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination's regulatory approval in the United States under a Metsera's HALO™ peptide stabilization and lipidation platformHALO™ is Metsera's novel peptide stabilization and lipidation platform technology that enables peptides to bind simultaneously to albumin and to a drug target, designed to facilitate a half-life approaching that of albumin and exceeding that of other NuSH peptides. This ultra-long half-life may enable monthly dosing, improved tolerability, and improved Metsera, is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; potential benefits of treatment with the Company's product candidates; and anticipated market opportunity and strategy. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which are accessible on the SEC's website at and the Investors section of the Company's website at Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact:Jono EmmettMetseramedia@

Prime Healthcare cutting 100 jobs across its Illinois facilities, months after acquiring hospitals from Ascension
Prime Healthcare cutting 100 jobs across its Illinois facilities, months after acquiring hospitals from Ascension

Chicago Tribune

time29 minutes ago

  • Chicago Tribune

Prime Healthcare cutting 100 jobs across its Illinois facilities, months after acquiring hospitals from Ascension

Prime Healthcare, which bought eight Illinois hospitals earlier this year, is eliminating more than 100 jobs, the hospital system confirmed Monday. Prime made most of the reductions Friday, and will continue cutting other jobs through July. 'As we continue to offer and create opportunities, we are also evaluating alignment with best practices and support from our national and regional teams,' Prime said in a statement. 'Through this process, there is a small number of positions that are duplicated or not aligned with the care model and service line offerings – most of them not directly providing patient care – that will be consolidated.' None of the affected jobs are union positions, according to Prime. Prime hired 13,000 workers from Ascension when it bought the hospitals from that health system, and has created nearly 1,000 new jobs since the acquisition. The job cuts represent less than 1% of the combined 14,000 employees, according to the statement. 'Importantly, these efforts will not affect the quality of care we deliver to the communities we serve and in fact will help expand best practices from across the nation,' Prime said in the statement. 'All decisions made at our Illinois facilities are guided by our mission to improve quality, strengthen care delivery, preserve access in underserved areas and ensure long-term sustainability.' The California-based Prime bought the Illinois hospitals for more than $370 million in March. Six of the hospitals sold to Prime changed from being nonprofit hospitals to for-profit hospitals as part of the sale. Hospitals that were sold include St. Mary's Hospital in Kankakee, Holy Family Medical Center in Des Plaines, Resurrection Medical Center in Chicago, St. Francis Hospital in Evanston, St. Joseph Medical Center in Joliet, St. Joseph Hospital in Elgin, Mercy Medical Center in Aurora and St. Mary of Nazareth Hospital in Chicago. The job cuts are the latest in a string of changes Prime has made since closing the deal, drawing criticism from elected officials and a nurses' union. Prime announced in April that it planned to suspend inpatient pediatric care at St. Joseph Medical Center in Joliet, saying at the time that the unit had been averaging less than one patient a day, while the need for other services such as advanced surgical, neurosurgical and spinal care had grown. The Illinois Nurses Association condemned the move arguing it would hurt the community, which only has one hospital. Also, Mercy Medical Center in Aurora lost its designation in April as a Level II trauma center. Prime also suspended obstetrical services at St. Mary's in Kankakee after the hospital's 'nearly sole obstetrics physician' retired, and because of low demand, Prime has said. Sen. Dick Durbin and Tammy Duckworth sent a letter to Prime's chairman, founder and CEO Dr. Prem Reddy, in May expressing concern about those changes and asking Prime to elaborate on the reasons behind them and its future plans for the hospitals. Prime responded to that letter last week, emphasizing its mission of turning around struggling community hospitals across the country. Prime said that before it bought the hospitals in Illinois they were losing about $200 million a year. Prime said maintaining services with low patient demand is not sustainable, nor good for the quality of care. Prime also told the senators it plans to expand behavioral health care services for seniors at its Illinois facilities. In its statement Monday, Prime said it has started fulfilling a previously stated commitment to invest $250 million across the Illinois hospitals. Prime said those affected by the job cuts are invited to apply for any of the more than 900 open positions across its Illinois facilities. The job cuts were first reported by the Herald News.

Health Insurers Call Out Trump On Promise To Not Cut Seniors' Medicare
Health Insurers Call Out Trump On Promise To Not Cut Seniors' Medicare

Forbes

timean hour ago

  • Forbes

Health Insurers Call Out Trump On Promise To Not Cut Seniors' Medicare

The nation's health insurance companies say legislation wending its way through the Republican-controlled Congress would break a promise by Donald Trump and the GOP not to cut Medicare benefits to seniors. It's the latest part of the healthcare industry to fight back against proposed federal cuts in healthcare benefits to millions of Americans. Already, physicians led by the American Medical Association have launched an ad campaign targeting U.S. Senators in an effort to thwart the budget legislation. Legislation known as the 'One Big Beautiful Bill Act' that narrowly passed the Republican-controlled U.S. House of Representatives two weeks ago would reduce federal Medicaid spending by $793 billion and increase the number of uninsured by 7.8 million, a KFF analysis shows. But the powerful lobby, America's Health Insurance Plans (AHIP) said Medicare, too, would be cut and raise costs on millions of seniors. AHIP's members include some of the nation's largest health insurers, including Elevance Health, Humana, CVS Health's Aetna and an array of Blue Cross and Blue Shield plans. These health insurers, including UnitedHealth Group's UnitedHealthcare, provide health benefits to more than half of the nation's eligible seniors through privatized coverage known as Medicare Advantage. The plans contract with the federal government to provide traditional coverage available in traditional Medicare plus extra benefits and services to seniors, such as disease management and nurse help hotlines with some also offering vision, dental care and wellness programs. 'The President and Congressional leaders made a clear promise to seniors that there would be no cuts to Medicare as part of the budget reconciliation legislation," AHIP President and CEO Mike Tuffin said Monday. 'Last-minute attempts to cut Medicare Advantage to fund other priorities would directly undermine that promise and lead to higher costs and reductions in benefits for more than 34 million seniors,' Tuffin said. "We oppose cuts to Medicare Advantage, including the No UPCODE Act, and urge Congress to keep the promise to America's seniors.' Any loss in health plan members covered by Medicare Advantage would be an added blow to health insurers. They need large numbers of subscribers paying premiums to cover their costs. Many of these same health insurers have been hit hard by rising costs from an influx of seniors purchasing Medicare Advantage.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store